Brief: Targovax Receives FDA Approval
Sept 27 (Reuters) - Targovax ASA TRVX.OL :
* RECEIVES APPROVAL TO PROCEED WITH THE ONCOS-102 PHASE 2
MELANOMA
STUDY FROM THE US FDA
* STUDY IS ON TRACK TO START IN LATE 2022 OR EARLY 2023
Source text for Eikon: ID:nObiVYdF4a
Further company coverage: TRVX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Circio Holding ASA
See all newsBrief: Circio, Genassist Jointly Announce Gene Therapy Research Collaboration
Brief: Circio And Aavigen To Collaborate On In Heart Gene Therapy
Brief: Circio Commences Exercise Period For Warrants
Brief: Circio Holding Files New Circvec Patent Application
Brief: Circio, Traffikgene Enter Research Collaboration